In this article, we will discuss Zanubrutinib (Dosage Overview). So, let’s get started.
Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The recommended dose of Zanubrutinib is 160 mg taken orally twice daily or 320 mg taken orally once daily until disease progression or unacceptable toxicity. Zanubrutinib can be taken with or without food. Advise patients to swallow capsules whole with water. Advise patients not to open, break, or chew the capsules. If a dose of Zanubrutinib is missed, it should be taken as soon as possible on the same day with a return to the normal schedule the following day.
Dosage Modification for Use in Hepatic Impairment
The recommended dose of Zanubrutinib for patients with severe hepatic impairment is 80 mg orally twice daily.